3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026

CRISPR Therapeutics' Casgevy accrued $76 million of revenue in Q2, up 78% year over year, although treatment completion timing delays formal revenue recognition. Analysts expect the company to report $156 million in 2027 sales versus roughly $41 million this year, rising to more than $600 million by 2028. The article highlights pipeline catalysts including CTX310's 50%-80% ANGPTL3 reductions in phase 1 and expected CTX611 phase 2 updates, supported by $2.3 billion of accessible liquidity.

Analysis

The investable issue is not whether Casgevy demand exists, but whether treatment-center throughput and manufacturing turnaround convert accrued economics into recognized revenue fast enough to support consensus. CRSP's share of the program is structurally lower quality than headline gross sales because Vertex controls commercialization and the therapy requires complex conditioning, collection, manufacturing, and transplant capacity. Over the next 1-3 months, reported treatment starts, authorized treatment-center expansion, and any update to revenue-recognition timing matter more than broad gene-editing enthusiasm.

VRTX is the cleaner way to own Casgevy execution: it has diversified cash generation and can absorb a slower launch, whereas CRSP remains valued largely on distant platform optionality. A slower ramp would disproportionately pressure CRSP's multiple and force investors to refocus on cash burn; a faster ramp can still leave CRSP lagging if investors view the economics as insufficient to fund wholly owned in-vivo programs. The key second-order beneficiary of successful ex-vivo adoption is not necessarily another editor, but specialized cell-processing and transplant infrastructure, where capacity remains the practical bottleneck.

CTX310 and CTX611 are potential repricing events, but early biomarker reductions should not be treated as cardiovascular-outcome validation. In-vivo editing faces a materially higher safety bar than rare-disease ex-vivo therapy: liver toxicity, off-target editing, durability, and immunogenicity can change the addressable market abruptly. The bullish consensus also understates platform fragmentation—NTLA, BEAM, EDIT and private developers can capture modality-specific value even if CRISPR editing becomes commercially important.

Contrarian view: the stock may be under-owned rather than fundamentally cheap. CRSP has enough liquidity to avoid near-term financing risk, so a clinically clean update could drive a sharp sentiment move; however, absent quantified dosing, safety, and durable efficacy data, the market should not capitalize broad platform revenue at mature-pharma multiples. This is a catalyst trade, not yet a durable earnings-compounder thesis.

Key Decisions for Investors

• Maintain a modest long CRSP only into the next disclosed clinical and operational updates; size as binary-risk biotech exposure. Add only if Casgevy treatment starts and recognized-revenue visibility indicate a 2027 trajectory above current consensus, not merely accrued program sales.
• Prefer long VRTX / short CRSP as a 3-6 month relative-value expression if Casgevy launch data remain opaque: VRTX retains upside to execution with materially lower single-asset and funding risk. Exit the pair if CRSP provides clear evidence of accelerating recognized revenue or decisive in-vivo efficacy with clean safety.
• Do not buy CTX310 optionality ahead of data without confirmation of dose cohorts, durability, liver safety, and editing specificity. Set an event watch for those disclosures; a clinically meaningful safety signal would invalidate a long thesis regardless of lipid biomarker magnitude.
• For CRSP longs, use a hard thesis review following any cash-burn guidance increase, Casgevy revenue-recognition delay, or regulatory safety communication. The principal downside is multiple compression from 'platform' to cash-consuming development-stage biotech, which can occur well before formal trial failure.